Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics.
about
Pharmacogenetics in type 2 diabetes: influence on response to oral hypoglycemic agentsPharmacogenomics of Drug Metabolizing Enzymes and Transporters: Relevance to Precision MedicineThe Role of Metformin Response in Lipid Metabolism in Patients with Recent-Onset Type 2 Diabetes: HbA1c Level as a Criterion for Designating Patients as Responders or Nonresponders to MetforminMembrane transporters in drug developmentIndividualized therapy for type 2 diabetes: clinical implications of pharmacogenetic data.Reduced physiologically-based pharmacokinetic model of repaglinide: impact of OATP1B1 and CYP2C8 genotype and source of in vitro data on the prediction of drug-drug interaction risk.Prediction of hepatic clearance in human from in vitro data for successful drug development.In vitro metabolism of exemestane by hepatic cytochrome P450s: impact of nonsynonymous polymorphisms on formation of the active metabolite 17β-dihydroexemestaneCyanobacterial Toxins of the Laurentian Great Lakes, Their Toxicological Effects, and Numerical Limits in Drinking WaterHuman liver expression of CYP2C8: gender, age, and genotype effects.Pharmacogenomics of oral antidiabetic medications: current data and pharmacoepigenomic perspective.Impact of OATP transporters on pharmacokinetics.Pharmacogenetics of OATP (SLC21/SLCO), OAT and OCT (SLC22) and PEPT (SLC15) transporters in the intestine, liver and kidney.Cerivastatin, genetic variants, and the risk of rhabdomyolysis.Cytochrome P450 2C8 pharmacogenetics: a review of clinical studiesCharacterization of organic anion transporting polypeptide 1b2-null mice: essential role in hepatic uptake/toxicity of phalloidin and microcystin-LR.Contribution of hepatic organic anion-transporting polypeptides to docetaxel uptake and clearanceRare versus common variants in pharmacogenetics: SLCO1B1 variation and methotrexate dispositionCYP2C8 but not CYP3A4 is important in the pharmacokinetics of montelukast.The impact of CYP2C8 polymorphism and grapefruit juice on the pharmacokinetics of repaglinide.Effect of SLCO1B1 genetic polymorphism on the pharmacokinetics of nateglinideThe effects of human CYP2C8 genotype and fluvoxamine on the pharmacokinetics of rosiglitazone in healthy subjects.SLCO1B1 521T-->C functional genetic polymorphism and lipid-lowering efficacy of multiple-dose pravastatin in Chinese coronary heart disease patientsEstimation of the effect of SLCO1B1 polymorphisms on lopinavir plasma concentration in HIV-infected adults.SLCO1B1 Variants and Angiotensin Converting Enzyme Inhibitor (Enalapril)-Induced Cough: a Pharmacogenetic Study.Organic anion transporting polypeptides OATP1B1 and OATP1B3 and their genetic variants influence the pharmacokinetics and pharmacodynamics of raloxifeneNeuroD1 A45T and PAX4 R121W polymorphisms are associated with plasma glucose level of repaglinide monotherapy in Chinese patients with type 2 diabetes.Pharmacogenomics of drug metabolizing enzymes and transporters: implications for cancer therapy.Influence of SLCO1B1 and CYP2C8 gene polymorphisms on rosiglitazone pharmacokinetics in healthy volunteersNo significant effect of SLCO1B1 polymorphism on the pharmacokinetics of rosiglitazone and pioglitazone.Role of the liver-specific transporters OATP1B1 and OATP1B3 in governing drug elimination.Clinical implications of CYP3A polymorphisms.Frequencies of single-nucleotide polymorphisms and haplotypes of the SLCO1B1 gene in selected populations of the western balkans.Expressed sequence tags (ESTs) and single nucleotide polymorphisms (SNPs): what large-scale sequencing projects can tell us about ADME.Influence of drug transporter polymorphisms on pravastatin pharmacokinetics in humans.Discordant associations between SLCO1B1 521T→C and plasma levels of ritonavir-boosted protease inhibitors in AIDS clinical trials group study A5146.Cytochrome P450 reaction-phenotyping: an industrial perspective.Pharmacogenetics of glucose-lowering drug treatment: a systematic review.Transporter-mediated uptake into cellular compartments.Role of OATP transporters in the disposition of drugs.
P2860
Q26751138-5B70AECF-5288-44FD-84EE-7A2ABE2E015EQ27692687-8CD76609-747F-4E64-82DA-65B58EF9F229Q28550746-9DF5FBAF-901F-4D87-A8CF-2C8B6DD0D2E4Q29616802-D25241B0-FAE3-4FDC-BFF6-838C7F72C14EQ30571118-B7C5821B-CAF7-4256-BFDF-8C5AF307321FQ30776360-C042579F-BCB0-46B6-B3DE-E599D3F2B9CCQ33437736-99DC3673-38EB-48C9-AD26-70B606C1BB10Q33777963-3B134A9D-DE55-4C49-A03B-52DBA9F09E61Q33833344-5E3CC8E8-A6CF-463B-9B25-BD4DE8A8B772Q33891033-4F9B54FD-9F04-4748-9493-EDC71CD4D977Q33993320-6679114B-A747-43BA-813B-681D71E3B6A3Q34612244-834C70B6-547A-4DDB-A063-7A91C4567E79Q34777362-03C79BE8-8538-4492-AF52-1EBD18042AC6Q34792178-DB8FC23D-5C3B-427A-A137-DA6F9B42DC9DQ35003605-AFC476D1-0906-46A2-9C51-0CB0E110FA70Q35234128-5AF476A4-182C-4440-ABBB-1757C1F571A7Q35375045-A24C083D-CD96-48FA-9A84-FAE0AF60F606Q35634476-7D5AF633-CB48-4823-9763-B7875A0E55C7Q35718619-4CD54496-1B94-41F0-84FD-DA8B3E32C13DQ35827353-C143E5D7-9835-4898-92F6-F2372FBA4B47Q35827882-02378702-58AE-43B4-A413-D586CDC209DEQ35827919-F4B487B3-0D86-44AE-9D7D-818281356717Q36024636-1B88B17C-8F5D-47A3-976B-95F476C52C64Q36238198-F11DAB14-4A5A-43F6-AAA2-59A2CE839BD1Q36321069-AFE7DFB7-2437-42AF-85C7-11D4C8A9DA98Q36334805-CA173A42-E120-4A89-B19F-CE1EABF29CFFQ36336051-77191624-C150-4ED5-BF71-6FACD18EA9DDQ36441493-248560FE-9C51-48DA-8092-E6052EF6686FQ36475040-FC2D5FB7-3E0E-4E6E-A80E-FF8FEAC94911Q36536042-2F2A5B85-AB70-4522-A9AD-326E067422BDQ36544966-9D02BE4B-54A3-48E7-AB80-600601647686Q36546247-D329A617-E7E0-44D1-A421-41D4251558F5Q36623470-6559E3AB-C5EB-4EA1-9B43-C4826E5BF42FQ36659874-2DB23EF5-D6DF-4933-93FF-D5390F9DB0FFQ36687277-38C5A832-4F5E-4879-A969-3C6158B034B5Q36701911-341DC1F6-7DBF-4F8A-BA85-9515463C512DQ36960539-E29E5D76-4FBB-4756-BCB4-0DB15BBF42ACQ36982648-28594B59-D368-473D-937D-98D765BAF770Q36985076-CEE7AA1D-CA65-46AA-B72C-C164CFE34855Q37074085-9CC81E1F-A301-4BB1-B327-44A50B22D7C6
P2860
Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
Polymorphic organic anion tran ...... repaglinide pharmacokinetics.
@en
Polymorphic organic anion tran ...... repaglinide pharmacokinetics.
@nl
type
label
Polymorphic organic anion tran ...... repaglinide pharmacokinetics.
@en
Polymorphic organic anion tran ...... repaglinide pharmacokinetics.
@nl
prefLabel
Polymorphic organic anion tran ...... repaglinide pharmacokinetics.
@en
Polymorphic organic anion tran ...... repaglinide pharmacokinetics.
@nl
P2093
P50
P1476
Polymorphic organic anion tran ...... repaglinide pharmacokinetics.
@en
P2093
Janne T Backman
Julian B Leathart
Kari T Kivistö
Lauri I Kajosaari
Michel Eichelbaum
Pertti J Neuvonen
P304
P356
10.1016/J.CLPT.2005.01.018
P407
P577
2005-06-01T00:00:00Z